AstraZeneca PLC is one of the world’s leading multinational pharmaceutical companies, headquartered in London, United Kingdom, with operations in more than 100 countries.
The company is publicly listed on the London Stock Exchange (LSE) under the stock ticker symbol ‘AZN’ – with secondary listings on the New York Stock Exchange and OMX.
It has a broad portfolio of products for the treatment of cancer, inflammation, neuroscience, cardiovascular conditions, infection, gastrointestinal conditions, and respiratory conditions.
AstraZeneca PLC was formed in 1999 following a merger between two pharmaceutical companies with similar visions: Astra AB of Sweden (founded in 1913) and Zeneca Group PLC (formed in 1993) of the UK.
Astra AB primarily marketed four main product groups: gastrointestinal, respiratory, cardiovascular, and pain control. It also operated Astra Tech – the company’s medical devices group.
Zeneca was a big bioscience group that created pharmaceuticals, with a focus on cardiovascular, cancer, respiratory, anesthesia, and central nervous system (CNS) drugs.
Since the merger of the two companies AstraZeneca has operations in over 100 countries, and in 2011 it was the tenth-largest pharmaceutical company worldwide with a primary listing on the London Stock Exchange.
Its corporate headquarters are in London, United Kingdom, its research and development headquarters are in Södertälje, Sweden, and the largest single research and development site is located at Alderley Park, Cheshire, England.
- CEO: Pascal Soriot
- Chairman: Leif Johansson
- Type: Public
- Industry: Pharmaceutical
- Founded: 1999
- Listed publicly on the LSE, NYSE, and OMX
- LSE stock ticker symbol: AZN
- NYSE stock ticker symbol: AZN
- OMX stock ticker symbol: AZN
- Revenue: $26.095 billion USD (2014)
- Net income: $1,235 million USD (2014)
- Diluted earnings per $0.25 of ordinary share: $0.98 USD (2014)
- Employees: 57,500 (2014)
- Company head office: 2 Kingdom Street, London W2 6BD, UK
- Corporate contact number: +44 (0)20 7604 8000
- Investor relations email: [email protected]
- Website: http://www.astrazeneca.com/
AstraZeneca PLC Financial Results, Years Ended December 31
|Income data (in $ millions)||2014||2013|
|Cost of sales||$(5,842)||$(5,261)|
|Research and development expense||$(5,579)||$(4,821)|
|Selling, general and administrative costs||$(13,000)||$(12,206)|
|Other operating income and expense||$787||$595|
|Profit before tax||$1,246||$3,267|
|Profit for the period||$1,235||$2,571|
|Comprehensive income for the period||$(271)||$2,458|
|Balance sheet data (in $ millions)|
|Cash flow data (in $ millions)|
|Net cash inflow from operating activities||$7,058||$7,400|
|Net cash outflow from investing activities||$(7,032)||$(2,889)|
|Net cash outflow from financing activities||$(2,705)||$(3,047)|
|Net (decrease)/increase in cash and cash equivalents in the period||$(2,679)||$1,464|
|Cash and cash equivalents at the end of the period||$6,164||$8,995|
|Common share data (in $)|
|Earnings per Common Share – Basic||$0.98||$2.04|
|Earnings per Common Share – Diluted||$0.98||$2.04|
Source: “AstraZeneca PLC Form 10-K 2014”